Banner
Home
Search by IDs Search by Gene
Browse
Patient Tumour & Clinical details PDX & PDXBiomarker details
Update
With gene expression Without gene expression Mutation & CNV Plot
Summary

Searching Database & Compiling the results...

This process involves analyzing complex genetic data and may take a moment.




PDX model details

PDX ID 386R
Host Strain(and Source) NSG
Source: Monash University
Host Strain Immune system Humanized NO
Host Type Testosterone supplemented
Graft Site Renal
Current Generation
(* indicates number of generations grown in Castrate host)
 12
Average PDX Generation Time (days +/- SEM) 135 ± 10
Tumour preparation Tumor solid
Tumour Characterization Technology Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq
Tumour confirmed not to be of Mouse/EBV origin Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC
Passage QA performed Routine QA every 2-3 passages
Associated meta data
PDX model availability Yes (fixed, frozen)
Governance restriction for distribution Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements
Pubmed ID 34413304
Markers 386R
AR Y
PSA Y
PSMA Y
NE N
ERG Y
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.

PDX ID Gene Symbol CNV Log2 CNV Copy CNV Call Experiments name Platform Reference genome
386R PIK3CB 0.501 2.829 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
386R PIK3CA 1.913 7.534 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
386R CHD7 0.490 2.809 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
386R MYC 0.490 2.809 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
386R MLH1 -0.756 1.185 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
386R CTNNB1 -0.756 1.185 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
386R SETD2 -0.756 1.185 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
386R CDH1 -0.761 1.180 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
386R ZFHX3 -0.761 1.180 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
386R FANCA -0.761 1.180 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
386R TP53 -0.770 1.173 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19

Clinical Information

Sample Number 386R
Sample Site Prostate
Sample source Radical prostatectomy
Pathology Tumour Diagnosis Adenocarcinoma
Gleason Score 9
Primary Gleason Score 4
Secondary Gleason Score 5
Tertiary Gleason Score None
ISUP Grade Group 5
Tumour Grade pT3bN1
D'Amico Risk Classification 7
Tumour Volume (in cc) 36.0
Treatment Prior to Specimen Collection None

Patient Information

Patient Number 386
Sex Male
Diagnosis Prostate Cancer
PSA at diagnosis (ng/mL) 6.98
Consent to share data Yes, subject to ethical review

Patient Tumour Collection (Current Model)
Tumour sample ID 386R
Patient Age (binned in 5 year age groups) 70-74
This heatmap displays the mutations of curated sequence variants.
Download Plot
The Mut plot is not shown
PDX ID Gene Symbol Total Read Depth Alternate Frequency Consequence Exon GnomAD AF CADD PHRED score ClinVar significance Platform Experiments Name Reference Library Type Instrument Type
386R ZNF717 10 1.0 Stop gained '5/5 . 23.7 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
386R ZNF717 10 1.0 Stop gained '5/5 . 23.7 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
386R FANCD2 344 0.77 Missense variant '16/43 4.06E-06 27.8 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
386R TP53 679 0.7 Frameshift variant '10/11 . . - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
386R GATA2 1326 0.66 Missense variant '6/6 4.48E-05 28.6 Uncertain significance Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
386R APC 549 0.49 Missense variant '16/16 . 26.2 Conflicting interpretations of pathogenicity Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
386R APC 666 0.48 Missense variant '16/16 0.0002035 23.3 Conflicting interpretations of pathogenicity Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500